Citadel Advisors
BCAB

Citadel Advisors’s BIOATLA INC BCAB Stock Holding History

Citadel Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24
Closed -$416 – 12561
2025
Q1 		$416 Sell
24
-852
-97% -$18.2K ﹤0.01% 14266
2024
Q4 		$25.9K Buy
876
+206
+31% +$17.3K ﹤0.01% 13003
2024
Q3 		$59K Buy
670
+522
+353% +$43.8K ﹤0.01% 11730
2024
Q2 		$10.1K Buy
148
+56
+61% +$6.66K ﹤0.01% 13104
2024
Q1 		$15.8K Sell
92
-18
-16% -$2.24K ﹤0.01% 13163
2023
Q4 		$13.5K Buy
110
+28
+34% +$2.43K ﹤0.01% 12925
2023
Q3 		$6.97K Sell
82
-28
-25% -$3.57K ﹤0.01% 13286
2023
Q2 		$16.5K Sell
110
-86
-44% -$14.8K ﹤0.01% 12895
2023
Q1 		$26.3K Buy
196
+154
+367% +$27.7K ﹤0.01% 12850
2022
Q4 		$17.3K Sell
42
-498
-92% -$207K ﹤0.01% 13254
2022
Q3 		$208K Buy
540
+82
+18% +$26.8K ﹤0.01% 10326
2022
Q2 		$65K Buy
+458
New +$72.9K ﹤0.01% 11757

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's BCAB Position: Q2 2026 in Review

Citadel Advisors sold out of BIOATLA INC (BCAB) in Q2 2026, closing a stake of 8,714 shares — an estimated $70.1K sold.

Citadel Advisors first reported a position in BCAB in Q4 2020 and held it in 18 quarters. The position peaked at $6.48M in Q2 2021. 21 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

  • Citadel Advisors reported no remaining BIOATLA INC position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 8,714 BIOATLA INC shares in Q2 2026, an estimated $70.1K.
  • Citadel Advisors first reported a position in BIOATLA INC in Q4 2020 and held it in 18 quarters.
  • Citadel Advisors's BIOATLA INC position peaked at $6.48M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held BIOATLA INC as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.